Abstract: Diabetes technology is currently focused on developing the artificial pancreas -a closed-loop control algorithm linking continuous glucose monitoring (CGM) and subcutaneous insulin delivery. The future development of the artificial pancreas will be greatly accelerated by employing mathematical modeling and computer simulation. Such in silico testing would provide direction for clinical studies, outruling ineffective control scenarios in a cost-effective manner. Thus, computer simulation testing of closed-loop control algorithms is regarded as a prerequisite to clinical trials of artificial pancreas. We therefore present a system for in silico testing of control algorithms consisting of a simulated human metabolic system, simulated CGM and simulated insulin pump. Further, we present an overview of current in vivo clinical trials of CGM and closed-loop control and illustrate the positive effects of CGM by data collected in a clinical trial using the Freestyle Navigator T M (Abbott Diabetes Care, Alameda, CA).
INTRODUCTION
Over thirty years ago, the possibility for external regulation of blood glucose (BG) in people with diabetes has been established by studies using intravenous (i.v.) glucose measurement and i.v. infusion of glucose and insulin to maintain normoglycemia by exerting both positive (via glucose or glucagon) and negative (via insulin) control. Systems, such as GCIIS or the better known Biostator, have been introduced and used in hospital setting Pfeiffer et al. (1974) , Albisser et al. (1974) , Clemens et al. (1977) , Marliss et al. (1977) , Santiago et al. (1979) . These systems were based on variants of the proportional integral derivative (PID) strategy: the injected insulin is proportional to the difference between a fixed target and the measured plasma glucose, as well as to the glucose rate of change. Other types of controllers have also been designed; some based on model-predictive (MPC) strategies counteracting the inherent inertia of exogenous insulin. The major designs can be found in Kraegen et al. (1977) , Fischer et al. (1978) , Clemens (1979) , Broekhuyse et al. (1981) , Salzsieder et al. (1985) . More work followed, spanning a broader range of control techniques, such as pole placement Salzsieder et al. (1985) , adaptive control Fischer et al. (1987) , physiologic modeling Sorensen (1985) , or linear quadratic Gaussian optimization (LQG) Ollerton (1989) , Fischer (1991) . However, i.v. closed-loop control remains cumbersome and unsuited for outpatient use. An alternative to extracorporeal i.v. control is presented by implantable i.v.-i.p. systems employing intravenous sampling and intra-peritoneal (i.p.) insulin delivery Leblanc et al. (1986) , Selam et al. (1992) , Renard (2002) . Recently, with the advent of minimally-invasive subcutaneous (s.c.) continuous glucose monitoring (CGM), increasing academic, industrial, and political effort has been focused on the development of s.c.-s.c. systems, generally using CGM coupled with insulin infusion pump and a control algorithm Klonoff (2007) . So far, encouraging pilot results have been reported Steil et al. (2006 ), Weinzimer (2006 The principal components of computer simulation environment recreating in silico a closed-loop control system are presented in Figure 1 :
A sufficiently large cohort of in silico 'subjects" based on real individual data and spanning the observed variability of key parameters in the general population;
b. Sensor-specific simulator of sensor errors, capable of reproducing the time lag, system and calibration bias, and random noise of s.c. CGM or implantable devices; c. The model of an insulin pump ensuring discrete insulin delivery and accounting for engineering limitations and the time lag inherent with s.c. insulin injection.
Silicon Sensor
• Calibration errors;
• Interstitial delay;
• Transient loss of sensitivity.
Silicon Insulin Pump
• Discrete insulin delivery;
• Subcutaneous insulin kinetics. 
Silicon Subject

In silico "subjects"
In silico "subjects" are typically created by fitting a metabolic model to data of individuals collected during clinical trials. Various metabolic models , Dalla Man et al. (2007b); Hovorka (2005) , Sorensen (1985) ) have been developed to serve this purpose, with the first two already used for testing of control scenarios.
As an example of building an in silico "subject" we present the glucose fluxes (i.e. rate of appearance, endogenous glucose production, etc.) postulated by the Glucose-Insulin Model :
Here G p and G t (mg/kg) are glucose masses in plasma and rapidly-equilibrating tissues, and in slowly-equilibrating tissues, respectively, G (mg/dl) is plasma glucose concentration, suffix b denotes basal state, EGP is endogenous glucose production (mg/kg/min), Ra is glucose rate of appearance in plasma (mg/kg/min), E is renal excretion (mg/kg/min), U ii and U id are insulin-independent and dependent glucose utilizations, respectively (mg/kg/min), V G is the distribution volume of glucose (dl/kg), and k 1 and k 2 (min −1 ) are rate parameters. In addition to glucose fluxes, the detailed model contains equations of insulin kinetics, as well as a compartmental representation of glucose intestinal absorption and the glucose transit through the stomach and intestine. Glucose excretion by the kidney, which occurs if plasma glucose exceeds a certain threshold, is modeled as well Dalla . Once the set of equations defining in silico "subjects" is laid out, in silico "population" is created by generating parameter vectors spanning the parameter space of the subject population. As an example of the utility of this approach, a recently developed in silico "population" containing 300 "subjects" in three age groups has been approved by the FDA as a substitute to animal trial in the pre-clinical testing of closed-loop control algorithms.
In silico sensor
In silico sensor is developed on the basis of a detailed analysis of sensor errors. In general, continuous glucose monitors (CGM) provide detailed time series of consecutive observations upon the underlying process of glucose fluctuations. However, a number of studies have concluded that despite eight years of development, the CGM technology continues to face challenges in terms of sensitivity, stability, calibration, and the physiological time lag between blood and interstitial glucose concentration Gerritsen et al. Zisser et al. (2008) . While testing sensor accuracy, these studies have typically generated large amounts of sensor-reference glucose data pairs, thereby allowing the decomposition of sensor errors into errors due to calibration, blood-to-interstitial glucose transfer, and random noise King et al. (2007) . After generating a random calibration error, the components of sensor error can be modeled as:
(i) Blood-to-interstitium glucose transport described by the equation:
17th IFAC World Congress (IFAC'08) where IG is the interstitial and BG is plasma glucose concentration, and τ represents the time lag between the two fluids;
(ii) Noise of the sensor, which is non-white (Gaussian). We therefore use ARMA process for its modeling. e 1 = v 1 e n = 0.7(e n−1 + v n ) with v n ∼ Φ(0, 1), i.i.d.. The sensor noise is ε n , which is driven by the normally distributed time series e n . The parameters ξ, λ, δ, and γ are the Johnson system (SUunbounded system) parameters corresponding to empirical noise distributions established in accuracy trials:
In silico insulin pump
In silico insulin pump is used to model subcutaneous insulin delivery. This has two major specifics that need to be taken into account: (i) time and dynamics of insulin transport from subcutaneous compartment into blood, and (ii) discrete insulin infusion corresponding to stepwise basal pump rate and insulin boluses. Several models of subcutaneous insulin kinetics have been published Nucci et al. (2000), Wilinska et al. (2005) . For example, a two compartment model can be assumed to describe insulin kinetics:
with I l (0) = I lb , I p (0) = I pb , I(0) = I b where Ip and Il (pmol/kg) are insulin masses in plasma and in liver, respectively, I (pmol/l) plasma insulin concentration, suffix b denotes basal state, Pump is the external subcutaneous insulin pump; m 1 , m 2 , m 3 , m 4 (min −1 ) are rate parameters. If implantable insulin pump is to be simulated, different models reflecting the kinetics of i.v. insulin would need to be used.
Exemplifying the "in silico" testing of a pre-meal insulin bolus, Figure 2 presents the glycemic reaction of three "silicon subjects" after a meal containing 75 grams of carbohydrate, while Figure 3 presents the reaction of one "subject" to three meals with different carbohydrate content: 75, 85, and 95 grams.
IN VIVO TRIALS OF CONTINUOUS GLUCOSE MONITORING AND CLOSED-LOOP CONTROL CONTINUOUS GLUCOSE MONITORING
The feedback of detailed continuous monitoring information to patients with diabetes has been shown to have positive influence on their glycemic control, including reduction in glucose variability, time spent in nocturnal hypoglycemia, time spent in hyperglycemia, and lower glycosylated hemoglobin Klonoff (2005) , Garg et al. (2006) , Deiss et al. (2006) , Kovatchev et al. (2007) . As reported recently, the first effects occurring within days of initiation of CGM were marked reductions in glucose variability and associated risks, not accompanied by reduction in average glycemia Kovatchev et al. (2007b) . The proposed here criteria have been shown to be quite sensitive to these effects ),McCall et al. (2006 . Thus, in addition to traditional characteristics such as average BG and time within target range, we suggest computing in one-hour increments: (i) the Low Blood Glucose Index (LBGI), which captures the risk of the control algorithm triggering hypoglycemia; (ii) the High Blood glucose index (HBGI), which captures the propensity of the algorithm to stay above the target range, and (iii) the absolute rate of glucose change, which captures the smoothness of the algorithm. To illustrate these measures, Figure 4 presents the effect of CGM in a group of 123 patients who were kept blinded to the readings of the device (Freestyle Navigator 
